TrilliumBiO and Oncobit Partner to Bring Novel Uveal Melanoma Monitoring Solution to the U.S.

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

TrilliumBiO-Oncobit

More Like This

PR Newswire associated0

TrilliumBiO and Oncobit Launch Advanced Uveal Melanoma Monitoring Solution in the U.S.

Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

PR Newswire associated0

Menarini Silicon Biosystems announces new study results on use of CELLSEARCH® liquid biopsy for earlier detection of relapse and to help inform decisions on patient management in stage III Melanoma

Jo Gumbs, CEO and Founder of Ocular Melanoma UK

Groundbreaking Treatment for Metastatic Uveal Melanoma Approved for Use in the UK

CIZZLE BIOTECHNOLOGY ANNOUNCES GROUNDBREAKING COLLABORATION WITH MOFFITT CANCER CENTER TO ADVANCE EARLY-STAGE LUNG CANCER DETECTION

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care

PR Newswire associated0

Calyx Medical Imaging Supports Groundbreaking Melanoma Treatment Approval

NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response